PET imaging using a 64Cu- or 89Zr-labeled monoclonal antibody against mesothelin as well as therapeutical usage of antibody-drug conjugate treatment has shown promising results in pancreatic and/or ovarian cancer [35, 36]. This evidence concerns the gene MSLN and ovarian cancer.